2,351 Shares in Quest Diagnostics Incorporated (NYSE:DGX) Purchased by BankPlus Wealth Management LLC

BankPlus Wealth Management LLC acquired a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 2,351 shares of the medical research company’s stock, valued at approximately $355,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Versant Capital Management Inc boosted its stake in Quest Diagnostics by 340.4% during the fourth quarter. Versant Capital Management Inc now owns 251 shares of the medical research company’s stock worth $38,000 after acquiring an additional 194 shares in the last quarter. First Financial Corp IN bought a new stake in shares of Quest Diagnostics in the 4th quarter worth approximately $38,000. Sunbelt Securities Inc. purchased a new stake in shares of Quest Diagnostics in the 2nd quarter worth approximately $40,000. Global Trust Asset Management LLC purchased a new stake in shares of Quest Diagnostics in the 4th quarter worth approximately $49,000. Finally, Sentry Investment Management LLC bought a new position in Quest Diagnostics during the 3rd quarter valued at approximately $82,000. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Analyst Ratings Changes

DGX has been the topic of a number of recent research reports. Baird R W raised Quest Diagnostics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 23rd. Piper Sandler raised their price objective on shares of Quest Diagnostics from $150.00 to $165.00 and gave the company a “neutral” rating in a research note on Monday, October 28th. Citigroup upped their target price on shares of Quest Diagnostics from $165.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Robert W. Baird raised shares of Quest Diagnostics from a “neutral” rating to an “outperform” rating and raised their price target for the company from $157.00 to $182.00 in a research report on Wednesday, October 23rd. Finally, Mizuho increased their target price on Quest Diagnostics from $160.00 to $174.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. Seven investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Quest Diagnostics currently has a consensus rating of “Moderate Buy” and an average price target of $172.15.

Quest Diagnostics Trading Up 3.0 %

Quest Diagnostics stock opened at $159.94 on Tuesday. The business has a 50-day simple moving average of $155.66 and a two-hundred day simple moving average of $153.21. Quest Diagnostics Incorporated has a 52-week low of $123.04 and a 52-week high of $165.32. The company has a quick ratio of 1.17, a current ratio of 1.25 and a debt-to-equity ratio of 0.83. The company has a market cap of $17.85 billion, a P/E ratio of 21.50, a P/E/G ratio of 2.36 and a beta of 0.90.

Quest Diagnostics Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 29th. Shareholders of record on Tuesday, January 14th will be issued a dividend of $0.75 per share. The ex-dividend date is Tuesday, January 14th. This represents a $3.00 dividend on an annualized basis and a yield of 1.88%. Quest Diagnostics’s dividend payout ratio is currently 40.32%.

Insiders Place Their Bets

In other Quest Diagnostics news, CAO Michael J. Deppe sold 18,755 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $154.05, for a total value of $2,889,207.75. Following the completion of the sale, the chief accounting officer now owns 34,941 shares in the company, valued at $5,382,661.05. This represents a 34.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.79% of the company’s stock.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.